search
Back to results

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Primary Purpose

Advanced Cancer

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BMS-986288
Nivolumab
Regorafenib
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies

Exclusion Criteria:

  • Active, known or suspected autoimmune disease
  • Active malignancy requiring concurrent intervention
  • Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded

Other protocol-defined inclusion/exclusion criteria apply

Sites / Locations

  • University of California, Irvine (UCI) Health Cancer Center - Newport/Costa Mesa
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center
  • Stanford University Medical Center
  • University Of ColoradoRecruiting
  • University of Florida College of Medicine
  • AdventHealth Orlando
  • Johns Hopkins UniversityRecruiting
  • Washington UniversityRecruiting
  • Hackensack University Medical CenterRecruiting
  • Local Institution - 0011Recruiting
  • Local Institution - 0074
  • Local Institution - 0014Recruiting
  • Local Institution - 0013Recruiting
  • Local Institution - 0008Recruiting
  • Local Institution - 0012Recruiting
  • Local Institution - 0017Recruiting
  • Local Institution - 0016Recruiting
  • Local Institution - 0006Recruiting
  • Local Institution - 0041
  • Local Institution - 0046
  • Local Institution - 0042
  • Local Institution - 0019Recruiting
  • Local Institution - 0009Recruiting
  • Local Institution - 0036Recruiting
  • Local Institution - 0035Recruiting
  • Local Institution - 0010Recruiting
  • Local Institution - 0034
  • Hôpital Nord Guillaume-et-René-Laennec / CHU de NantesRecruiting
  • Hospices Civils de Lyon - Hopital Louis PradelRecruiting
  • Assistance Publique Hôpitaux de Marseille - Hôpital NordRecruiting
  • Institut CurieRecruiting
  • Centre Hospitalier intercommunal de Toulon La Seyne sur MerRecruiting
  • Local Institution - 0040Recruiting
  • Local Institution - 0038Recruiting
  • Local Institution - 0028Recruiting
  • Local Institution - 0033Recruiting
  • Local Institution - 0031Recruiting
  • Local Institution - 0027
  • Local Institution - 0039Recruiting
  • Local Institution - 0056
  • Local Institution - 0054
  • Local Institution - 0023Recruiting
  • Local Institution - 0024Recruiting
  • Local Institution - 0055
  • Local Institution - 0025Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Arm A: BMS-986288 Monotherapy

Arm B: BMS-986288 in combination with Nivolumab

Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib

Arm Description

Outcomes

Primary Outcome Measures

Incidence of Adverse Events (AEs)
Incidence of Serious Adverse Events (SAEs)
Incidence of AEs meeting protocol-defined Dose Limiting Toxicities (DLT) criteria
Incidence of AEs leading to discontinuation
Incidence of AEs leading to death
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review
Part 2C

Secondary Outcome Measures

Maximum Observed Concentration (Cmax) of BMS-986288
Time of Maximum Observed Concentration (Tmax) of BMS-986288
Area Under the Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration AUC(0-T) of BMS-986288
Area Under the Concentration-Time Curve in one Dosing Interval AUC(TAU) of BMS-986288
Observed Concentration at the end of a Dosing Interval (Ctau) of BMS-986288
Trough Observed Concentrations (Ctrough) of BMS-986288
Total Body Clearance (CLT) of BMS-986288
Average Concentration Over a Dosing Interval at Steady State (Cavgss) of BMS-986288
Accumulation Index (AI) of BMS-986288
Terminal Half-Life (T-HALF) of BMS-986288
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator assessment
Duration of Response (DOR) by RECIST v1.1 by Investigator Assessment
Progression-Free Survival (PFS) by RECIST v1.1 by Investigator Assessment
Time to Response (TTR) by RECIST v1.1 by Investigator Assessment
DOR by RECIST v1.1 by blinded independent central review
PFS by RECIST v1.1 by blinded independent central review
Overall Survival (OS) by RECIST v1.1 by blinded independent central review
Incidence of Adverse Events (AEs)
Incidence of Serious Adverse Events (SAEs)
Incidence of AEs meeting protocol-defined Dose Limiting Toxicities (DLT) criteria
Incidence of AEs leading to discontinuation
Incidence of AEs leading to death

Full Information

First Posted
June 17, 2019
Last Updated
October 11, 2023
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT03994601
Brief Title
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Official Title
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 6, 2019 (Actual)
Primary Completion Date
April 14, 2024 (Anticipated)
Study Completion Date
May 14, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
494 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A: BMS-986288 Monotherapy
Arm Type
Experimental
Arm Title
Arm B: BMS-986288 in combination with Nivolumab
Arm Type
Experimental
Arm Title
Part 2C: BMS-986288 in combination with Nivolumab and Regorafenib
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BMS-986288
Intervention Description
Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Other Intervention Name(s)
Opdivo, BMS-936558
Intervention Description
Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Intervention Description
Specified dose on specified days
Primary Outcome Measure Information:
Title
Incidence of Adverse Events (AEs)
Time Frame
Up to 2 years
Title
Incidence of Serious Adverse Events (SAEs)
Time Frame
Up to 2 years
Title
Incidence of AEs meeting protocol-defined Dose Limiting Toxicities (DLT) criteria
Time Frame
Up to 2 years
Title
Incidence of AEs leading to discontinuation
Time Frame
Up to 2 years
Title
Incidence of AEs leading to death
Time Frame
Up to 2 years
Title
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review
Description
Part 2C
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Maximum Observed Concentration (Cmax) of BMS-986288
Time Frame
Up to 2 years
Title
Time of Maximum Observed Concentration (Tmax) of BMS-986288
Time Frame
Up to 2 years
Title
Area Under the Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration AUC(0-T) of BMS-986288
Time Frame
Up to 2 years
Title
Area Under the Concentration-Time Curve in one Dosing Interval AUC(TAU) of BMS-986288
Time Frame
Up to 2 years
Title
Observed Concentration at the end of a Dosing Interval (Ctau) of BMS-986288
Time Frame
Up to 2 years
Title
Trough Observed Concentrations (Ctrough) of BMS-986288
Time Frame
Up to 2 years
Title
Total Body Clearance (CLT) of BMS-986288
Time Frame
Up to 4 months
Title
Average Concentration Over a Dosing Interval at Steady State (Cavgss) of BMS-986288
Time Frame
Up to 4 months
Title
Accumulation Index (AI) of BMS-986288
Time Frame
Up to 4 months
Title
Terminal Half-Life (T-HALF) of BMS-986288
Time Frame
Up to 4 months
Title
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator assessment
Time Frame
Up to 4 years
Title
Duration of Response (DOR) by RECIST v1.1 by Investigator Assessment
Time Frame
Up to 4 years
Title
Progression-Free Survival (PFS) by RECIST v1.1 by Investigator Assessment
Time Frame
Up to 4 years
Title
Time to Response (TTR) by RECIST v1.1 by Investigator Assessment
Time Frame
Up to 4 years
Title
DOR by RECIST v1.1 by blinded independent central review
Time Frame
Up to 4 years
Title
PFS by RECIST v1.1 by blinded independent central review
Time Frame
Up to 4 years
Title
Overall Survival (OS) by RECIST v1.1 by blinded independent central review
Time Frame
Up to 4 years
Title
Incidence of Adverse Events (AEs)
Time Frame
Up to 100 days following last dose of study treatment
Title
Incidence of Serious Adverse Events (SAEs)
Time Frame
Up to 100 days following last dose of study treatment
Title
Incidence of AEs meeting protocol-defined Dose Limiting Toxicities (DLT) criteria
Time Frame
Up to 100 days following last dose of study treatment
Title
Incidence of AEs leading to discontinuation
Time Frame
Up to 100 days following last dose of study treatment
Title
Incidence of AEs leading to death
Time Frame
Up to 100 days following last dose of study treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy Eastern Cooperative Oncology Group Performance Status of 0 or 1 Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies Exclusion Criteria: Active, known or suspected autoimmune disease Active malignancy requiring concurrent intervention Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded Other protocol-defined inclusion/exclusion criteria apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone
855-907-3286
Email
Clinical.Trials@bms.com
First Name & Middle Initial & Last Name or Official Title & Degree
First line of the email MUST contain NCT # and Site #.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
University of California, Irvine (UCI) Health Cancer Center - Newport/Costa Mesa
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92627
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Farshid Dayyani, Site 0075
Phone
714-456-5153
Facility Name
University of California, Irvine (UCI) Health - UC Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Farshid Dayyani, Site 0050
Phone
714-456-5153
Facility Name
Stanford University Medical Center
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Holden, Site 0053
Phone
650-498-6000
Facility Name
University Of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Davis, Site 0005
Phone
720-848-0300
Facility Name
University of Florida College of Medicine
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas George, Site 0069
Phone
352-273-7832
Facility Name
AdventHealth Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamedtaki Tejani, Site 0051
Phone
215-707-2777
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dung Le, Site 0002
Phone
443-287-0002
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Morgensztern, Site 0004
Phone
314-747-7948
Facility Name
Hackensack University Medical Center
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Gutierrez, Site 0001
Phone
551-996-5863
Facility Name
Local Institution - 0011
City
Ciudad Autónoma De Buenos Aires
State/Province
Buenos Aires
ZIP/Postal Code
1426
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0011
Facility Name
Local Institution - 0074
City
Buenos Aires
State/Province
Ciudad Autónoma De Buenos Aires
ZIP/Postal Code
C1096AAS
Country
Argentina
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0074
Facility Name
Local Institution - 0014
City
Córdoba
State/Province
Cordoba
ZIP/Postal Code
X5000HXL
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0014
Facility Name
Local Institution - 0013
City
Río Cuarto
State/Province
Cordoba
ZIP/Postal Code
5800
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0013
Facility Name
Local Institution - 0008
City
ABB
State/Province
Distrito Federal
ZIP/Postal Code
C1199
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0008
Facility Name
Local Institution - 0012
City
Caba
State/Province
Distrito Federal
ZIP/Postal Code
C1430
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0012
Facility Name
Local Institution - 0017
City
Buenos Aires
ZIP/Postal Code
1431
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0017
Facility Name
Local Institution - 0016
City
Buenos Aires
ZIP/Postal Code
C1280AEB
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0016
Facility Name
Local Institution - 0006
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0006
Facility Name
Local Institution - 0041
City
Laval
State/Province
Quebec
ZIP/Postal Code
H7M 3L9
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0041
Facility Name
Local Institution - 0046
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0046
Facility Name
Local Institution - 0042
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 1P1
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0042
Facility Name
Local Institution - 0019
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
7510032
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0019
Facility Name
Local Institution - 0009
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
8420383
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0009
Facility Name
Local Institution - 0036
City
Santiago
State/Province
Región Metropolitana De Santiago
ZIP/Postal Code
7500921
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0036
Facility Name
Local Institution - 0035
City
Santiago
State/Province
Región Metropolitana De Santiago
ZIP/Postal Code
7620002
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0035
Facility Name
Local Institution - 0010
City
Viña del Mar
State/Province
Valparaiso
ZIP/Postal Code
2520598
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0010
Facility Name
Local Institution - 0034
City
Bordeaux
State/Province
Gironde
ZIP/Postal Code
33075
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0034
Facility Name
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
City
Saint-Herblain
State/Province
Loire-Atlantique
ZIP/Postal Code
44800
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elvire Pons-Tostivint, Site 0022
Phone
+33676133810
Facility Name
Hospices Civils de Lyon - Hopital Louis Pradel
City
Bron Cedex
ZIP/Postal Code
69677
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Duruisseaux, Site 0018
Phone
33427857700
Facility Name
Assistance Publique Hôpitaux de Marseille - Hôpital Nord
City
Marseille
ZIP/Postal Code
13915
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurent Greillier, Site 0026
Phone
33491324400
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
75248
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
nicolas girard, Site 0015
Phone
+33624456290
Facility Name
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
City
Toulon
ZIP/Postal Code
83100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clarisse Audigier-Valette, Site 0021
Phone
33494145610
Facility Name
Local Institution - 0040
City
Milan
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0040
Facility Name
Local Institution - 0038
City
Padova
State/Province
Veneto
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0038
Facility Name
Local Institution - 0028
City
Ancona
ZIP/Postal Code
60126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0028
Facility Name
Local Institution - 0033
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0033
Facility Name
Local Institution - 0031
City
Milan
ZIP/Postal Code
20162
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0031
Facility Name
Local Institution - 0027
City
Monza
ZIP/Postal Code
20900
Country
Italy
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0039
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0039
Facility Name
Local Institution - 0056
City
Barcelona
State/Province
Barcelona [Barcelona]
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0056
Facility Name
Local Institution - 0054
City
Barcelona
State/Province
Catalunya [Cataluña]
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0054
Facility Name
Local Institution - 0023
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0023
Facility Name
Local Institution - 0024
City
Majadahonda
ZIP/Postal Code
28222
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0024
Facility Name
Local Institution - 0055
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0055
Facility Name
Local Institution - 0025
City
València
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0025

12. IPD Sharing Statement

Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
http://www.BMSStudyConnect.com
Description
BMS Clinical Trial Patient Recruiting
URL
http://www.fda.gov/safety/medwatch/safetyinformation/default.htm
Description
FDA Safety Alerts and Recalls
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
Investigator Inquiry Form

Learn more about this trial

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

We'll reach out to this number within 24 hrs